Department of Gastroenterology, Hematology, Medical Oncology and Endocrinology, Klinikum Dortmund, Klinikum of the University Witten/Herdecke, Dortmund, Germany.
Clinical Outcomes Assessment, Clarivate Analytics, London, UK.
Adv Ther. 2024 Sep;41(9):3598-3614. doi: 10.1007/s12325-024-02939-1. Epub 2024 Jul 25.
Understanding the patient journey of hepatocellular carcinoma (HCC) may inform future clinical decision-making and enhance the patient experience. The objectives of this study were to explore the patient experience of HCC in relation to treatment options, treatment decision-making and treatment goals throughout the disease journey. This study also aimed to determine the symptoms and impacts of HCC across early, intermediate and advanced HCC.
Semi-structured 60-min interviews were conducted with n = 50 patients with HCC and n = 12 healthcare professionals (HCPs) with experience of treating patients with HCC. Interview data were analyzed using directed content analysis techniques with a hybrid inductive and deductive approach. An assessment of conceptual saturation was conducted for patients' symptom experience.
Patients described treatment decisions as mostly HCP-led. In this study, surgery/resection was the most frequently offered treatment option across the HCC journey, and most patients were satisfied with the treatment options presented to them. Overall, patients described extending their overall survival (OS) and preserving quality of life (QoL) as their most important treatment goals, with patients diagnosed with advanced/unresectable HCC prioritizing QoL. HCPs also prioritized OS and progression-free survival (PFS) though reported that QoL became more important as HCC progressed. Patients experienced various symptoms across the HCC journey including fatigue, nausea, appetite loss, diarrhea and pain.
Overall, HCPs and patients collaborate throughout the treatment journey regarding treatment decisions and shared treatment goals. OS is critically important to patients and HCPs, though treatment goals may change depending on various clinical factors.
了解肝细胞癌(HCC)患者的就医历程可能有助于未来的临床决策并改善患者体验。本研究旨在探讨 HCC 患者在整个疾病过程中与治疗选择、治疗决策和治疗目标相关的就医体验。本研究还旨在确定早期、中期和晚期 HCC 患者的症状和影响。
对 50 名 HCC 患者和 12 名具有治疗 HCC 患者经验的医疗保健专业人员(HCP)进行了 60 分钟的半结构式访谈。使用定向内容分析技术,采用归纳和演绎相结合的混合方法对访谈数据进行分析。对患者症状体验进行了概念饱和度评估。
患者将治疗决策描述为主要由 HCP 主导。在本研究中,手术/切除是整个 HCC 病程中最常提供的治疗选择,大多数患者对向他们提供的治疗方案感到满意。总体而言,患者将延长总体生存期(OS)和保持生活质量(QoL)描述为他们最重要的治疗目标,诊断为晚期/不可切除 HCC 的患者优先考虑 QoL。HCP 也将 OS 和无进展生存期(PFS)作为治疗目标,尽管他们报告称,随着 HCC 的进展,QoL 变得更加重要。患者在 HCC 病程中经历了各种症状,包括疲劳、恶心、食欲减退、腹泻和疼痛。
总体而言,HCP 和患者在整个治疗过程中就治疗决策和共同的治疗目标进行合作。OS 对患者和 HCP 至关重要,但治疗目标可能因各种临床因素而改变。